Suetonia C Palmer, Lucia Di Micco, Mona Razavian, Jonathan C Craig, Vlado Perkovic, Fabio Pellegrini, Massimiliano Copetti, Giusi Graziano, Gianni Tognoni, Meg Jardine, Angela Webster, Antonio Nicolucci, Sophia Zoungas, Giovanni F M Strippoli
BACKGROUND: Antiplatelet agents are used to prevent cardiovascular events; however, treatment effects may differ in persons with chronic kidney disease (CKD) because atherosclerotic disease is less prevalent, whereas bleeding hazards may be increased in this population. PURPOSE: To summarize the effects of antiplatelet treatment on cardiovascular events, mortality, and bleeding in persons with CKD. DATA SOURCES: Embase and Cochrane databases through November 2011 without language restriction...
March 20, 2012: Annals of Internal Medicine